Browsing ICR Divisions by author "Woolston, Andrew"
Now showing items 1-10 of 10
-
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy.
Knebel, FH; Barber, LJ; Newey, A; Kleftogiannis, D; Woolston, A; et al. (MDPI, 2020-12-11)Epidermal growth factor receptor antibodies (EGFR-Abs) confer a survival benefit in patients with RAS wild-type metastatic colorectal cancer (mCRC), but resistance invariably occurs. Previous data showed that only a minority ... -
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; et al. (OXFORD UNIV PRESS INC, 2021-01-04)BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ... -
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; et al. (MDPI, 2019-06-04)DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ... -
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data.
Khan, K; Gonzalez-Exposito, R; Cunningham, D; Koh, D-M; Woolston, A; et al. (FRONTIERS MEDIA SA, 2020-09-04)BACKGROUND: Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic ... -
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.
von Loga, K; Woolston, A; Punta, M; Barber, LJ; Griffiths, B; et al. (NATURE PUBLISHING GROUP, 2020-01-16)Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically ... -
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; et al. (CELL PRESS, 2019-06-26)Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ... -
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey, A; Griffiths, B; Michaux, J; Pak, HS; Stevenson, BJ; et al. (BMC, 2019-10-08)BACKGROUND: Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics ... -
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.
Woolston, A; Barber, LJ; Griffiths, B; Pich, O; Lopez-Bigas, N; et al. (NATURE PORTFOLIO, 2021-05-20)Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which mutational mechanisms enable resistance evolution and ... -
Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
Mansukhani, S; Barber, LJ; Kleftogiannis, D; Moorcraft, SY; Davidson, M; et al. (OXFORD UNIV PRESS INC, 2018-08-27)BACKGROUND: Circulating free DNA sequencing (cfDNA-Seq) can portray cancer genome landscapes, but highly sensitive and specific technologies are necessary to accurately detect mutations with often low variant frequencies. ...